The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): The phase 3 DETERMINATION trial.
 
Paul G. Richardson
Consulting or Advisory Role - Celgene; Janssen; Jazz Pharmaceuticals; Karyopharm Therapeutics; Oncopeptides; Sanofi; Secura Bio; Takeda
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Oncopeptides (Inst); Takeda (Inst)
 
Susanna J. Jacobus
No Relationships to Disclose
 
Edie Weller
No Relationships to Disclose
 
Hani Hassoun
Consulting or Advisory Role - Novartis
Research Funding - Janssen; Takeda
 
Sagar Lonial
Stock and Other Ownership Interests - TG Therapeutics
Consulting or Advisory Role - Abbvie; Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen Oncology; Merck; Novartis; Sanofi; Takeda
Research Funding - Bristol-Myers Squibb; Celgene; Takeda
Other Relationship - TG Therapeutics
 
Noopur S. Raje
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Caribou Biosciences; Celgene; Immuneel Therapeutics; Janssen Oncology; Merck; Pfizer; Takeda
Research Funding - Bluebird Bio (Inst)
 
Eva Medvedova
No Relationships to Disclose
 
Philip L. McCarthy
Honoraria - Bluebird Bio; Bristol-Myers Squibb; Celgene; Genentech; Hikma Pharmaceuticals; Janssen; Karyopharm Therapeutics; Novartis; Oncopeptides; Partner Therapeutics; STARTON Therapeutics; Takeda
Consulting or Advisory Role - Bluebird Bio; Bristol-Myers Squibb; Celgene; Janssen; Juno Therapeutics; Karyopharm Therapeutics; Magenta Therapeutics; MedGenome; Novartis; Sanofi; STARTON Therapeutics; Takeda
Research Funding - Celgene (Inst)
 
Edward N. Libby
Honoraria - Curio Science
Consulting or Advisory Role - Pharmacylics/Janssen
Research Funding - BeiGene (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Janssen (Inst)
 
Peter M. Voorhees
Consulting or Advisory Role - Abbvie/Genentech; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Oncopeptides; Pfizer; Sanofi; Secura Bio
Research Funding - Abbvie (Inst); GlaxoSmithKline (Inst); Janssen (Inst); TeneoBio (Inst)
Travel, Accommodations, Expenses - Sanofi
(OPTIONAL) Uncompensated Relationships - GlaxoSmithKline
 
Robert Z. Orlowski
Stock and Other Ownership Interests - Asylia Therapeutics, Inc.
Consulting or Advisory Role - Amgen; BioTheryX; Bristol-Myers Squibb; Celgene; Forma Therapeutics; Genzyme; GlaxoSmithKline; Ionis Pharmaceuticals; Janssen Biotech; Juno Therapeutics; Karyopharm Therapeutics; Kite, a Gilead Company; Legend Biotech; Molecular Partners; Neoleukin Therapeutics; Oncopeptides; Regeneron; Sanofi; SERVIER; Takeda
Research Funding - BioTheryX; CARsgen Therapeutics; Celgene; Exelixis; Heidelberg Pharma; Janssen Biotech; Sanofi; Takeda
 
Larry D. Anderson, Jr.
Honoraria - Abbvie; Amgen; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; janssen; Karyopharm Therapeutics; Oncopeptides; Prothena
Consulting or Advisory Role - Abbvie; amgen; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; janssen; Karyopharm Therapeutics; Oncopeptides; Prothena
Research Funding - amgen; bms; celgene; GlaxoSmithKline; janssen; Karyopharm Therapeutics
 
David D. Hurd
No Relationships to Disclose
 
Marcelo C. Pasquini
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Kite, a Gilead Company; Novartis
 
Kelly Masone
No Relationships to Disclose
 
Philippe Moreau
Honoraria - Abbvie; Amgen; Celgene; GlaxoSmithKline; Janssen-Cilag; oncopeptides; Sanofi
Consulting or Advisory Role - Abbvie; Amgen; Celgene; GlaxoSmithKline; Janssen; oncopeptides; Sanofi
 
Herve Avet-Loiseau
No Relationships to Disclose
 
Michel Attal
No Relationships to Disclose
 
Kenneth Carl Anderson
Leadership - C4 Therapeutics; Mana Therapeutics; NextRNA; OncoPep; Raqia; starton therapeutics
Stock and Other Ownership Interests - C4 Therapeutics; Mana Therapeutics; NextRNA; OncoPep; Raqia; STARTON Therapeutics
Consulting or Advisory Role - amgen; AstraZeneca; Bristol-Myers Squibb; Janssen Oncology; Millennium; oncopeptides; Pfizer; Precision Biosciences; Sanofi
Patents, Royalties, Other Intellectual Property - C4 Therapeutics; Oncopep
 
Nikhil C. Munshi
Stock and Other Ownership Interests - C4 Therapeutics; OncoPep; Raqia
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; Amgen; BeiGene; Bristol-Myers Squibb; Bristol-Myers Squibb/Celgene; Janssen; Karyopharm Therapeutics; Legend Biotech; Novartis; OncoPep; Raqia; Sebia; Takeda
Patents, Royalties, Other Intellectual Property - Oncopep